Clinical Trials
0
0 active
Approvals
2
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
- Taiwan Bio Therapeutics has partnered with Terumo Blood and Cell Technologies to transition regulatory T-cell manufacturing from manual processes to the automated Quantum Flex platform for improved scalability and repeatability. - The collaboration focuses on Taiwan Bio's TRK-001 therapy, currently in multicenter Phase 2 trials for preventing graft rejection in kidney transplantation patients. - The partnership will integrate Terumo's 3-in-1 automated protocol that combines cell activation, viral transduction, and expansion within a single closed bioreactor system. - Taiwan Bio plans to use this automated manufacturing foundation to advance at least one next-generation engineered Treg candidate to an Investigational New Drug application.
- Terumo Blood and Cell Technologies and Santersus AG announced an exclusive partnership to develop NucleoCapture blood purification technology combined with the Spectra Optia Apheresis System for sepsis treatment. - The FDA-designated Breakthrough Device selectively removes neutrophil extracellular traps (NETs) from blood plasma, targeting a key factor in sepsis progression that leads to organ failure. - Santersus will lead the pivotal NUC-CAP clinical study across the U.S., UK, and EU, while Terumo Ventures invests in the company's Series A financing round. - The technology has potential applications beyond sepsis, including Alzheimer's disease, systemic lupus erythematosus, and organ transplantation conditions.
- Terumo BCT has developed a new automated workflow that consolidates T cell activation, viral transduction, and expansion into a single platform, streamlining CAR-T manufacturing significantly. - The protocol demonstrates the ability to produce over 12 billion CAR-T cells in just 7 to 8 days with doubled transduction efficiency compared to manual methods. - The integrated 3-in-1 approach uses serum-free culture conditions and closed-system design to reduce contamination risks while supporting generation of crucial T cell subtypes including memory cells. - The workflow is currently under evaluation by cell therapy developers and is expected to shorten production timelines, lower costs, and expand patient access to CAR-T treatments.
• Gamma delta T cells demonstrate unique potential in treating solid tumors and autoimmune conditions, operating independently of HLA matching and showing minimal toxicity toward healthy cells. • Despite representing only 1-5% of total T cells in peripheral blood, gamma delta T cells are gaining attention with a 50% increase in companies pursuing their development over the past year. • Manufacturing challenges persist due to limited cell availability, but experts remain optimistic about scaling potential and advantages over traditional CAR-T therapies, particularly in reducing side effects like cytokine release syndrome.
